Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by muscle mass loss with or without a fat mass loss that is often associated with anorexia, the inflammatory process, insulin resistance, and increased protein turnover.
Currently, the Cachexia sphere constitutes a robust pipeline with more than 25+ drugs under different phases of development. And although there are so many Cachexia treatment therapies and a robust pipeline, there currently is no permanent cure found for cachexia. However, researchers are learning more about the processes that cause it.
DelveInsight offers a new addition to its newsletter edition that pivots on the Cachexia market. The newsletter provides a complete picture of the Cachexia market landscape, ongoing clinical trials, and pipeline therapies expected to transform the Cachexia market in the coming decade. Dive deep into rich insights of Cachexia epidemiological insights, current treatment therapies, details of the latest news and happenings, mergers and collaborations, major pharmaceuticals involved, licensing deals along with events, and top-level conferences.
Keen about what is in store for the Cachexia market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form on the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the ‘Wasting’ Disorders market.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Cachexia Epidemiological Trends
- Current Cachexia Treatment Regimen
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Cachexia Market Insights
- Cachexia Market Dynamics
- Collaborations & Fundings